Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Atypical antipsychotic wikipedia , lookup
Drug discovery wikipedia , lookup
Neuropsychopharmacology wikipedia , lookup
Neuropharmacology wikipedia , lookup
NK1 receptor antagonist wikipedia , lookup
Nicotinic agonist wikipedia , lookup
Theralizumab wikipedia , lookup
Cannabinoid receptor antagonist wikipedia , lookup
Urban legends about drugs wikipedia , lookup
SYNTHETIC CANNABINOIDS Shelley A. Holmer MD Duke University School of Medicine ©AMSP 2013 © AMSP 2013 1 CASE • 27 yo woman who presented with o Trembling o Confusion o Voices o Fears people want to harm her • No family history of psychosis • Medical work-up → no major medical dx • Recent use of the synthetic cannabinoids © AMSP 2013 2 THIS LECTURE WILL REVIEW • Background on cannabinoids • Development of synthetic cannabinoids (SC) • Risks associated with use • Synthetic cannabinoids versus marijuana © AMSP 2013 3 NATURAL CANNABINOIDS = MARIJUANA • • Comes from the plant Cannabis sativa • Composed of > 500 compounds • 66 compounds are "cannabinoids” © AMSP 2013 4 CANNABINOIDS Psychoactive • Tetrahydrocannabinols (THC) • Cannabinol (CBN) • Cannabinodiol (CBDL) Non-psychoactive • Cannabigerols (CBG) • Cannabichromenes (CBC) • Cannabidiols (CBD) © AMSP 2013 5 CANNABINOID RECEPTORS CB1 receptor • Psychoactive effects • In brain and spinal cord (CNS) • THC = partial agonist (positive effect) • CBD = blocker of CB1 CB2 receptors • Immune cells outside CNS • Immune function and inflammation © AMSP 2013 6 CANNABINOIDS: PSYCHOACTIVE EFFECTS • • • • • • • Euphoria Sensation of slowed time Impaired judgment Impaired coordination Social withdrawal Anxiety Psychosis © AMSP 2013 7 PSYCHOSIS • Hallucinations +/• Delusions • Without insight • Alert/oriented • Potential cannabinoid impact: o THC may ↑ psychosis o CBD may ↓ psychosis © AMSP 2013 8 NON-PSYCHOACTIVE EFFECTS • ↓ Nausea • ↑ Appetite • ↓ Pain © AMSP 2013 9 CHRONIC USE LEADS TO • Tolerance o Increased amount required for same effect o Diminished effect with use of same amount • Withdrawal symptoms when stopped o Irritability o Anxiety o ↓ Appetite o Sleep problems No legal detox • Peak ~3-4 days, resolves after ~7 days © AMSP 2013 10 THIS LECTURE WILL REVIEW • Background on cannabinoids • Development of synthetic cannabinoids (SC) • Risks associated with use • SC versus marijuana © AMSP 2013 11 SYNTHETIC CANNABINOIDS (SC) • Research compounds • None approved for humans • Most >potency than THC JWH18 • Full agonists at the CB1 receptor © AMSP 2013 12 SPICE: SC COMMERCIAL PRODUCTS • • • • • • • Spice K2 Red magic Red dragon Diesel Serenity Blueberry Meditation © AMSP 2013 13 SPICE • SC sprayed on substance • No dose control • No regulation of ingredients • Similar psychoactive effects to THC • Marketed as herbal incense “not for human use” © AMSP 2013 14 SPICE USE • First seen in Europe 2004 • First marketed in U.S. 2008 • 2012 used by 11 % of 12th graders © AMSP 2013 15 SPICE: MEDICAL RECOGNITION • Calls to US poison control centers o2010: 3000 o2011: 7000 o2012: 5000 • 11,406 ER visits in 2010 © AMSP 2013 16 LEGAL STATUS OF SPICE • 2008 Europe banned for health concerns • 2011 US federal law deemed “no medical use” • Possession illegal in 41 states • Remains available o Head shops o Convenience stores/gas stations o Internet © AMSP 2013 17 WHY IS IT POPULAR? • New/novel way to get “high” • False belief SC safe because o “Herbal” o Legal • Cannabis substitute • Might ↓ cannabis withdrawal • Inexpensive • Accessible © AMSP 2013 18 NOT DETECTED ON DRUG SCREENS • Athletes • Military personnel • Students • People on probation • Employees with required drug screens • Patients in drug tx programs © AMSP 2013 19 THIS LECTURE WILL REVIEW • Background on cannabinoids • Development of synthetic cannabinoids (SC) • Risks associated with use • SC versus marijuana © AMSP 2013 20 CASE Clinical Course • Pt immobile and incommunicative • Hospitalized 2 mo with psychosis • One year later psychosis free © AMSP 2013 21 CASE REPORTS: ACUTE TOXICITY Psychiatric • Agitation • Anxiety • Paranoia • Delusions William S. Burroughs, 1914-1997, “Self Portrait,” CU Libraries Exhibitions • Hallucinations © AMSP 2013 22 ACUTE TOXICITY Neurologic • Seizures • Dilated pupils • Jerking movements • Decreased reflexes © AMSP 2013 23 ACUTE TOXICITY Cardiovascular • ↑ Heart rate • ↑ Blood pressure • Chest pain © AMSP 2013 24 ACUTE TOXICITY Gastrointestinal • Nausea • Vomiting • Diarrhea © AMSP 2013 25 TREATMENT OF ACUTE INTOXICATION Psychiatric: anxiety and psychosis • Verbal reassurance “talk down” • Medication for agitation (lorazepam) • Seclusion/restraint only if serious danger • Evaluate need for ongoing psychiatric care © AMSP 2013 26 TREATMENT OF ACUTE INTOXICATION Neurologic • Seizure monitoring • Evaluate muscle injury o Muscle pain/weakness o Labs: ↓ kidney function © AMSP 2013 27 TREATMENT OF ACUTE INTOXICATION Cardiac • Monitor o Blood pressure o Heart rate • Check EKG • Labs: heart damage enzymes o Troponin > 0.2 ng/ml o CKMB > 3 ng/ml © AMSP 2013 28 TREATMENT OF ACUTE INTOXICATION Gastrointestinal • Medication for nausea • IV fluids • Labs: check for low potassium © AMSP 2013 29 LASTING CONSEQUENCES Heart attacks • 3 healthy adolescents with MI • No personal or family history • All smoked the SC “K2” © AMSP 2013 30 LASTING CONSEQUENCES May trigger psychosis if prior history • 15 forensic inpts with psychotic illness • All actively taking antipsychotics • 5 with relapse of psychotic symptoms • 24 hours after smoking JWH-018 © AMSP 2013 31 LASTING CONSEQUENCES May cause first episode psychosis • 10 men admitted for psychosis • 9 had no FH of psychosis • 7 needed meds • 3 still psychotic 5 mo later © AMSP 2013 32 LASTING CONSEQUENCES Self harm/suicide while intoxicated • Suicidal thoughts • Reports of self-injury © AMSP 2013 33 THIS LECTURE WILL REVIEW • Background on cannabinoids • Development of synthetic cannabinoids (SC) • Risks associated with use • SC versus marijuana © AMSP 2013 34 Marijuana vs Synthetic Cannabinoids • • • • Nature controls dose Low-medium potency Partial CB1 agonist Contains CBD • • • • © AMSP 2013 No dose control High potency Full CB1 agonist No CBD 35 COMPARING SC TO MARIJUANA (MJ) • MJ contains CBD: potential antipsychotic • Natural marijuana may ↓ seizures • No long-term SC studies © AMSP 2013 36 CLINICAL CONCLUSIONS • Data on optimal Rx not available • Need ask patients about SC use • Educate patients about SC risks © AMSP 2013 37 OVERALL CONCLUSIONS • Not a safe marijuana alternative • Easy to obtain despite ban • Inquire about use • Risks not commonly known by public • Not detected on urine tests © AMSP 2013 38